Back to top
more

Liquidia Technologies (LQDA)

(Delayed Data from NSDQ)

$11.09 USD

11.09
621,900

+0.05 (0.41%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $11.09 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Wall Street Analysts Believe Liquidia Technologies, Inc. (LQDA) Could Rally 74%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 74.1% in Liquidia Technologies, Inc. (LQDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 37.50% and 11.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of 71.43% and 8.08%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Lags Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 32.56% and 2.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is IQ Chaikin U.S. Small Cap ETF (CSML) a Strong ETF Right Now?

Smart Beta ETF report for CSML

Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?

Style Box ETF report for CSML

United Therapeutics (UTHR) Gains on Tyvaso DPI Approval

The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.

Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -50% and 7.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aveanna Healthcare (AVAH) Q1 Earnings Lag Estimates

Aveanna (AVAH) delivered earnings and revenue surprises of -33.33% and 4.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) Reports Q1 Loss, Lags Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of -11.43% and 19.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates

Insmed (INSM) delivered earnings and revenue surprises of 12.09% and 0.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -109.09% and 11.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is Liquidia Technologies, Inc. (LQDA) Stock Outpacing Its Medical Peers This Year?

Here is how Liquidia Technologies, Inc. (LQDA) and Assertio (ASRT) have performed compared to their sector so far this year.

Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -16.67% and 28.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 18.75% and 95.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Tops Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -5.00% and 260.28%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Rising P/E: An Overlooked Way to Pick 5 Winning Stocks

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter

The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form

Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne

Zacks.com featured highlights include: Minerva Neurosciences, Liquidia Technologies, Calix, Avenue Therapeutics and ExOne

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Why Liquidia Technologies (LQDA) Stock Might be a Great Pick?

Liquidia Technologies (LQDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Misses Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Liquidia Technologies, Inc. (LQDA) Report Negative Earnings Next Week? What You Should Know

Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Liquidia Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Liquidia.

Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?